On February 22, 2012, the fourth protocol amendment for our ongoing U.S. study of MDMA-assisted psychotherapy for veterans with PTSD received “unconditional approval” from the Institutional …
On February 22, 2012, the IRB approved the fourth amendment to our ongoing U.S. study of MDMA-assisted psychotherapy for veterans with PTSD.
On February 14, 2012, the fourth protocol amendment for our ongoing U.S. study of MDMA-assisted psychotherapy for PTSD in veterans of war was submitted to the IRB.
On February 10, 2012, MAPS’ clinical team submitted a protocol amendment to the FDA with several important changes to our ongoing U.S. study of MDMA-assisted psychotherapy for veterans with chronic, …
On December 1, 2011, the eighth (out of 16) veteran passed in-person screening for participation in our ongoing study of MDMA-assisted psychotherapy for U.S. veterans with PTSD. Five subjects have now …
As of October 21, 2011, our ongoing Phase 2 study of MDMA-assisted psychotherapy for U.S. veterans with chronic, treatment-resistant PTSD has enrolled five out of 16 subjects. Three subjects have started …
Five subjects (out of 16) have now received at least one experimental treatment session in our ongoing U.S. Phase 2 Study of MDMA-assisted psychotherapy for veterans with chronic, treatment-resistant PTSD. …
On August 4, 2011, the third protocol amendment for our ongoing U.S. study of MDMA-assisted psychotherapy for veterans with PTSD was submitted to the FDA.
On August 2, 2011, our clinical team submitted the third protocol amendment for our recently initiated U.S. study of MDMA-assisted psychotherapy for veterans with PTSD to the IRB for review.
On July 14, 2011, the second subject had their second open-label MDMA-assisted psychotherapy session in our ongoing US Phase 2 Study of MDMA-assisted psychotherapy for PTSD in veterans of war. This study …
On May 20, 2011, the first subject was unblinded in our ongoing US Phase 2 study of MDMA-assisted psychotherapy for PTSD in veterans of war. Now that the research team knows which dose of MDMA the subject …
On March 25, 2011, MAPS Lead Clinical Research Associate Berra Yazar-Klosinski, Ph.D., visited Charleston, SC, to evaluate the progress of our ongoing Phase 2 pilot study of MDMA-assisted psychotherapy …
